{"commentary":{"count":25,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":12,"podcast":8,"youtube":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01874171\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"De-ESCALaTE","nct_id":"NCT01874171","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=de-escalate-nct01874171. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"De-ESCALaTE","arms":[{"description":"Three doses of cisplatin 100mg/m2 given at days 1, 22 and 43 from start of radiotherapy.","label":"Cisplatin","type":"ACTIVE_COMPARATOR"},{"description":"Initial dose of 400mg/m2 one week before start of radiotherapy followed by seven weekly doses of 250 mg/m2 during radiotherapy.","label":"Cetuximab","type":"EXPERIMENTAL"}],"collaborators":["Cancer Research UK","University of Birmingham","University of Oxford"],"completion_date":{"date":"2019-02","type":"ESTIMATED"},"conditions":["Oropharyngeal Squamous Cell Carcinoma"],"enrollment":{"count":334,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Cisplatin","type":"DRUG"},{"name":"Cetuximab","type":"DRUG"}],"last_update":"2017-05-08","lead_sponsor":"University of Warwick","official_title":"Determination of Epidermal Growth Factor Receptor-inhibitor (Cetuximab) Versus Standard Chemotherapy (Cisplatin) Early And Late Toxicity Events in Human Papillomavirus-positive Oropharyngeal Squamous Cell Carcinoma","overall_status":"UNKNOWN","phases":["PHASE3"],"primary_completion_date":{"date":"2019-02","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Compare severe (acute and late) toxicity (Grade 3-5) caused by cetuximab and radiotherapy to that caused by cisplatin and radiotherapy.","timeFrame":"Up to two years after end of treatment."}],"references":[],"start_date":{"date":"2012-11-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC","url":"https://clinicaltrials.gov/study/NCT01874171"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/de-escalate-nct01874171"}